Larimar Therapeutics, Inc.8月5日成交额为2832.26万美元

市场透视2025-08-06

美东时间2025年8月5日，Larimar Therapeutics, Inc.（LRMR.US）成交额为2832.26万美元，成交额较昨日增加465.86%，当日成交量为723.78万股。Larimar Therapeutics, Inc.（LRMR.US）于2025年8月5日涨12.99%，报3.74美元，该股过去5个交易日涨5.95%，年初至今跌3.36%，过去60日涨66.96%。|近5个...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557344282?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-06 11:38","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557344282","market":"us","top_or_hot":-1,"title":"Larimar Therapeutics, Inc.8月5日成交额为2832.26万美元","media":"市场透视","content":"<div>\n<p>美东时间2025年8月5日，Larimar Therapeutics, Inc.（LRMR.US）成交额为2832.26万美元，成交额较昨日增加465.86%，当日成交量为723.78万股。Larimar Therapeutics, Inc.（LRMR.US）于2025年8月5日涨12.99%，报3.74美元，该股过去5个交易日涨5.95%，年初至今跌3.36%，过去60日涨66.96%。|近5个...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806113828a477ce6c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Larimar Therapeutics, Inc.8月5日成交额为2832.26万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLarimar Therapeutics, Inc.8月5日成交额为2832.26万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-06 11:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806113828a477ce6c&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美东时间2025年8月5日，Larimar Therapeutics, Inc.（LRMR.US）成交额为2832.26万美元，成交额较昨日增加465.86%，当日成交量为723.78万股。Larimar Therapeutics, Inc.（LRMR.US）于2025年8月5日涨12.99%，报3.74美元，该股过去5个交易日涨5.95%，年初至今跌3.36%，过去60日涨66.96%。|近5个...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806113828a477ce6c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806113828a477ce6c&s=b","article_id":"2557344282","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806113828a477ce6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557344282","pubTimestamp":1754451502,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美东时间2025年8月5日，Larimar Therapeutics, Inc.成交额为2832.26万美元，成交额较昨日增加465.86%，当日成交量为723.78万股。Larimar Therapeutics, Inc.于2025年8月5日涨12.99%，报3.74美元，该股过去5个交易日涨5.95%，年初至今跌3.36%，过去60日涨66.96%。其主打候选产品 CTI-1601 是一种皮下注射的重组融合蛋白，旨在将人类铁硫蛋白这种必需蛋白递送至弗里德赖希共济失调症患者的线粒体中。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","LRMR":"Larimar Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Larimar Therapeutics, Inc. turnover of $28.3226 M on August 5","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LRMR":1,"LENZ":1},"content_text":"美东时间2025年8月5日，Larimar Therapeutics, Inc.（LRMR.US）成交额为2832.26万美元，成交额较昨日增加465.86%，当日成交量为723.78万股。Larimar Therapeutics, Inc.（LRMR.US）于2025年8月5日涨12.99%，报3.74美元，该股过去5个交易日涨5.95%，年初至今跌3.36%，过去60日涨66.96%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-05|2832.26万|465.86%|723.78万|#|2025-08-04|500.52万|24.03%|152.07万|#|2025-08-01|403.55万|-34.77%|116.28万|#|2025-07-31|618.66万|-60.76%|174.51万|#|2025-07-30|1576.59万|210.05%|439.60万|Larimar Therapeutics Inc 是一家临床阶段的生物技术公司，专注于利用其创新的细胞穿透肽（CPP）技术平台，为患有复杂罕见疾病的患者开发治疗方案。其主打候选产品 CTI-1601 是一种皮下注射的重组融合蛋白，旨在将人类铁硫蛋白（FXN）这种必需蛋白递送至弗里德赖希共济失调症患者的线粒体中。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557344282","isCrawlerRequest":true}